FDA
-
-
-
-
-
-
-
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
-
-
-
-
-
-
-
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
-
-
-
-
-
-
-
Vaxart (VXRT) Prices 16M Share Offering
-
-
-
-
-
-
-
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
-
-
-
-
-
-
-
Vaxart Appoints W. Mark Watson to its Board of Directors
-
-
-
-
-
-
-
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
-
-
-
-
-
-
-
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
-
251,614 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All